New kidney drug tested for safety with statins and blood thinners
NCT ID NCT07515339
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see how a new experimental drug for chronic kidney disease, nurandociguat, affects the way the body processes two common medicines: rosuvastatin (a cholesterol drug) and dabigatran (a blood thinner). Healthy adults would have taken these drugs alone and then again after taking nurandociguat to compare drug levels and side effects. The study was withdrawn before any participants enrolled, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit
Mannheim, Baden-Wurttemberg, 68167, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk